Therapeutic drug monitoring of antipsychotics and clinical-psychological markers of the risk of aggressive behavior in schizophrenia: a two-component observational study
https://doi.org/10.65249/1027-7218-2026-9-16-23
Abstract
Objective. To examine clinical and psychological variables associated with hostility and anger and to assess the association of documented treatment nonadherence with subtherapeutic or undetectable antipsychotic concentrations in blood plasma in patients with schizophrenia and a history of aggressive behavior.
Materials and methods. A two-component observational study was conducted in two independent samples. The inpatient component included 56 patients assessed with PANSS, AIHQ, DAI-30, and other standardized instruments. The outpatient component included 63 patients receiving antipsychotic treatment; 45 had no documented history of treatment nonadherence and 18 had such a history. Plasma antipsychotic concentrations were measured using high-performance liquid chromatography with high-resolution mass spectrometric detection. Bonferroni correction was applied to 36 correlation tests (adjusted significance threshold, 0.0014).
Results. After correction for multiple testing, hostility and anger indices remained significantly associated with positive, negative, general psychopathology and supplementary PANSS scores, the PANSS total score, and scale 4 (Psychopathic Deviate) of the MiniMult inventory. In the outpatient sample, subtherapeutic or undetectable antipsychotic concentrations in blood plasma were found in 13 (72.2 %) of 18 patients with documented treatment nonadherence and in 17 (37.8 %) of 45 patients without such a history (χ² = 6.115, p = 0.013).
Conclusions. Therapeutic drug monitoring provides an objective measure of antipsychotic exposure and complements clinical assessment of adherence. These findings do not establish a causal effect of drug concentration on aggressive behavior and do not support the use of therapeutic drug monitoring as a stand-alone violence prediction tool.
About the Authors
A. KhodzhaevBelarus
Yu. Kaminskaya
Belarus
M. Skuharevskaya
Belarus
T. Golubeva
Belarus
M. Gnedko
Belarus
I. Dashkevich
Belarus
Yu. Pokhodnya
Belarus
V. Kulbatsky
Belarus
E. Pokhodnya
Belarus
A. Aleksandrov
Belarus
A. Volkevich
Belarus
V. Shakal
Belarus
I. Kononovich
Belarus
V. Anikeeva
Belarus
References
1. Whiting D., Gulati G., Geddes J.R., Fazel S. Association of schizophrenia spectrum disorders and violence perpetration in adults and adolescents from 15 countries. JAMA Psychiatry. 2022; 79(2): 120–132.
2. Fazel S., Gulati G., Linsell L., et al. Schizophrenia and violence. PLoS Med. 2009; 6(8). doi: 10.1371/journal.pmed.1000120.
3. Witt K., van Dorn R., Fazel S. Risk factors for violence in psychosis. PLoS One. 2013; 8(2). doi: 10.1371/journal.pone.0055942.
4. Woods P., Almvik R. The Broset violence checklist (BVC). Acta Psychiatr Scand Suppl. 2002; 412: 103–105.
5. Golenkov A.V., Underov D.A. Aggressive behavior of mentally ill patients during emergency psychiatric care. Psihicheskoe zdorov'e. 2016; 14(1): 9–15. (in Russian).
6. Lacro J.P., Dunn L.B., Dolder C.R., et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia. J Clin Psychiatry. 2002; 63(10): 892–909.
7. Higashi K., Medic G., Littlewood K.J., et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence. Ther Adv Psychopharmacol. 2013; 3(4): 200–218.
8. Dilla T., Ciudad A., Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013; 7: 275–284.
9. Potanin S., Morozova M.A., Beniashvili A.G., et al. Guideline for the use of therapeutic drug monitoring of antipsychotics to individualize the selection of therapy in the treatment of exacerbation of schizophrenia. Obozrenie psihiatrii i medicinskoj psihologii imeni V. M. Bekhtereva. 2023; 57(4): 111–119. (in Russian)
10. Hiemke C., Bergemann N., Clement H.W., et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 2018; 51(1–2): 9–62.
11. Schoretsanitis G., Kane J.M., Correll C.U., et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American society of clinical psychopharmacology and the Therapeutic drug monitoring task force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020; 81(3). doi: 10.4088/JCP.19cs13169.
12. Mauri M.C., Paletta S., Maffini M., et al. Clinical pharmacology of atypical antipsychotics: EXCLI J. 2014; 13: 1163–1191.
13. Velligan D.I., Medic G., Littlewood K.J., et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007; 58(9): 1187–1192.
14. Miroshnichenko I.I., Bajmeeva N.V., Platova A.I. Determination of serum/plasma concentrations of psychotropic drugs in therapeutic drug monitoring. Farmakokinetika i Farmakodinamika. 2021; (1): 3–13. (in Russian)
15. Wagner E., McMahon L., Falkai P., et al. Impact of smoking behavior on clozapine blood levels. Acta Psychiatr Scand. 2020; 142(6): 456–466.
Review
For citations:
Khodzhaev A., Kaminskaya Yu., Skuharevskaya M., Golubeva T., Gnedko M., Dashkevich I., Pokhodnya Yu., Kulbatsky V., Pokhodnya E., Aleksandrov A., Volkevich A., Shakal V., Kononovich I., Anikeeva V. Therapeutic drug monitoring of antipsychotics and clinical-psychological markers of the risk of aggressive behavior in schizophrenia: a two-component observational study. Healthcare. 2026;1(9):16-23. (In Russ.) https://doi.org/10.65249/1027-7218-2026-9-16-23
JATS XML
